Roivant Sciences Ltd. ROIV
Composite 40/100; the shares have moved about 40% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 1/100 — a strong mark against it.
Balance-sheet strength ranks 85/100 — a strong point in its favour. Momentum ranks 69/100 — a moderate point in its favour.
Growth ranks 1/100 — a strong mark against it. Quality ranks 10/100 — a strong mark against it. Valuation ranks 38/100 — a moderate mark against it.
What the company does Roivant Sciences Ltd. (ROIV) is a clinical-stage biopharma focused on discovering, developing, and commercializing medicines for immune-mediated and cardiopulmonary diseases. Its pipeline includes programs like IMVT-1402 (FcRn-targeting antibody), mosliciguat (inhaled sGC activator), and brepocitinib (TYK2/JAK1 inhibitor).
Key financials ROIV reports negative profitability with ROE -8%, ROA -14%, and ROCE -5%. Revenue fell 67% YoY, and EPS declined 96%. Debt/equity is low at 0.02, but net debt/EBITDA is high at 3.28. The company trades at EV/EBITDA 0.74 and P/B 5.56.
Stock health Momentum is strong over 6m (54%) and 12m (197%), though it’s down 9% from its 52-week high. Sideravia scores ROIV “Poor quality, fairly valued, positive momentum,” with strength at 85% and valuation at 59%.
Price vs fair value The stock trades at a discount of 14% to the 12-month analyst target of 39 (analyst count 11). - Analysts see 14% upside to 39 vs current 34 (analyst count 11). - Sideravia valuation percentile is 59, indicating fair valuation. - Momentum pillar is 77, supporting recent price strength. - Quality pillar is 13, weighing on fundamentals.
Looking forward Key catalysts include readouts for mosliciguat in pulmonary hypertension and brepocitinib in dermatomyositis. Analysts expect valuation expansion if Phase 2/3 data readouts are positive. Execution risk remains high given early-stage pipeline.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.